Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Ovarian Neoplasms 2Lymphoma 2Breast Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Neoplasm Metastasis 1Leukemia 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

fludarabine phosphate 7pembrolizumab 6Mycophenolic Acid 6Peripheral Blood Stem Cell Transplantation 5Nivolumab 5Cyclosporine 5Cyclophosphamide 5Whole-Body Irradiation 4Radiotherapy 3Busulfan 3Antilymphocyte Serum 3temsirolimus 2fludarabine 2atezolizumab 2alectinib 2Tacrolimus 2Sunitinib 2Specimen Handling 2Paclitaxel 2Methotrexate 2Magnetic Resonance Spectroscopy 2Drug Therapy 2Dasatinib 2Alemtuzumab 2varlilumab 1valspodar 1utomilumab 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × valspodar × Lymphoid × Clear all
NCT00001383 2008-03-04

A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
52 enrolled
BreastGenitourinaryGynecologicLymphoid

Breast Neoplasms, Carcinoma, Renal Cell, Lymphoma, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡